Literature DB >> 7705800

Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment.

O Reichard1, H Glaumann, A Frydén, G Norkrans, R Schvarcz, A Sönnerborg, Z B Yun, O Weiland.   

Abstract

Fourteen patients with chronic hepatitis C who had a sustained response to a 60-week interferon alfa-2b treatment course were followed, biochemically and virologically, 2 years after treatment cessation. Biopsies were repeated in 12 of 14 for histological and virological evaluation at 2-year follow-up. All 14 patients had normal serum alanine transaminase (s-ALT) levels and were negative for hepatitis C virus (HCV) RNA in serum during treatment and at short-term follow-up 6 months post-treatment. At 2-year follow-up, 13 patients still had normal ALT levels (< 0.6 mukat/L for women; < 0.8 mukat/L for men), 1 a near normal level (0.76 mukat/L); all were HCV RNA negative in serum, and 11 of 12 also in the liver. Liver histology improved during treatment and remained stable during the 2-year follow-up. The authors conclude that most sustained responders, who have normal ALT levels and are nonviremic at short-term follow-up 6 months after interferon treatment, will continue to have a durable long-term response without relapse of the viremia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7705800

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  11 in total

1.  Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection.

Authors:  Kiminori Uka; Fumitaka Suzuki; Norio Akuta; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

2.  Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C.

Authors:  M Y Sheikh; R A Wright; J B Burruss
Journal:  Dig Dis Sci       Date:  1998-03       Impact factor: 3.199

3.  Short-term versus sustained response to interferon therapy: effect on histology.

Authors:  O Reichard
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

4.  Predictors of response to interferon therapy.

Authors:  G Saracco; M Rizzetto
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

5.  Usefulness of a liver biopsy in the evaluation of patients with elevated ALT values and serological markers of hepatitis viral infection: an AIGO study.

Authors:  A Andriulli; V Festa; G Leandro; M Rizzetto
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

6.  Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

Authors:  U Siebert; G Sroczynski; S Rossol; J Wasem; U Ravens-Sieberer; B M Kurth; M P Manns; J G McHutchison; J B Wong
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

7.  Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment.

Authors:  A Mathew; L P Peiffer; K Rhoades; T McGarrity
Journal:  Dig Dis Sci       Date:  2006-09-27       Impact factor: 3.199

8.  Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease.

Authors:  Yukiko Saitou; Katsuya Shiraki; Yutaka Yamanaka; Yumi Yamaguchi; Tomoyuki Kawakita; Norihiko Yamamoto; Kazushi Sugimoto; Kazumoto Murata; Takeshi Nakano
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

9.  Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.

Authors:  Uwe Siebert; Gaby Sroczynski; Pamela Aidelsburger; Siegbert Rossol; Jürgen Wasem; Michael P Manns; John G McHutchison; John B Wong
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 10.  Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

Authors:  B J Veldt; G Saracco; N Boyer; C Cammà; A Bellobuono; U Hopf; I Castillo; O Weiland; F Nevens; B E Hansen; S W Schalm
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.